Skip to content

Study · Observational study · n = 828 · 2026

4 results

Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.

Maruyama F, Kitsunai H, Kitao N, Wakabayashi Y, Ito M, Kurihara H, Yamamoto C, Takeuchi J, Abiko A, Homma R, Miyamoto Y, Yamagata K, Miyazaki A, Nakamura A, Nomoto H

Diabetes, obesity & metabolism7 Apr 2026Cited by 2 (Europe PMC)

PMID41944182 (opens in a new tab)DOI10.1111/dom.70734 (opens in a new tab)PepBankPUB-41944182
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, glycated haemoglobin fell by 1.07% after 6 months of tirzepatide.

    In plain wordsIn adults with type 2 diabetes, glycated haemoglobin fell by 1.07% after 6 months of tirzepatide in routine care.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at 6 months
    Study

    n = 828

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −1.07%
    6 months

    Source sentences

    Summary
    glycated haemoglobin (-1.07%, 95% CI -1.16, -0.98; baseline 7.82% ± 1.59%, p < 0.001)
    2 context sentences
    Summary · context
    This multicenter retrospective observational study evaluated subjects with T2D who were treated with tirzepatide for ≥ 6 months across 10 medical centers in Hokkaido, Japan.
    Summary · context
    Of the 828 subjects analysed (mean age 55.6 ± 12.5 years; mean body mass index 30.6 ± 5.8), 81.3% were treated with incretin-based medications at baseline.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes in routine care, body weight fell by 3.1 kg after 6 months of tirzepatide.

    In plain wordsIn adults with type 2 diabetes, body weight fell by 3.1 kg after 6 months of tirzepatide in routine care.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at 6 months
    Study

    n = 828

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    body weight change
    −3.1 kg
    6 months

    Source sentences

    Summary
    body weight (-3.1 kg, 95% CI -3.4, -2.8; baseline 83.8 ± 18.5 kg, p < 0.001)
    2 context sentences
    Summary · context
    This multicenter retrospective observational study evaluated subjects with T2D who were treated with tirzepatide for ≥ 6 months across 10 medical centers in Hokkaido, Japan.
    Summary · context
    Of the 828 subjects analysed (mean age 55.6 ± 12.5 years; mean body mass index 30.6 ± 5.8), 81.3% were treated with incretin-based medications at baseline.
  3. 03HumanObservational studySafety outcome

    In adults with type 2 diabetes in routine care, tirzepatide was discontinued in 45 subjects because of adverse events, personal preference or other clinical reasons.

    In plain wordsIn adults with type 2 diabetes, 45 people stopped tirzepatide because of side effects, personal preference or other clinical reasons.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTreatment discontinuation
    Study

    n = 828

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    discontinuations
    45 subjects
    any reason

    Source sentences

    Summary
    Tirzepatide was discontinued in 45 subjects because of adverse events, personal preference or other clinical reasons.
    2 context sentences
    Summary · context
    This multicenter retrospective observational study evaluated subjects with T2D who were treated with tirzepatide for ≥ 6 months across 10 medical centers in Hokkaido, Japan.
    Summary · context
    Of the 828 subjects analysed (mean age 55.6 ± 12.5 years; mean body mass index 30.6 ± 5.8), 81.3% were treated with incretin-based medications at baseline.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes who switched from incretin-based medications, the efficacy of tirzepatide was consistent with that in the whole cohort.

    In plain wordsIn adults with type 2 diabetes who switched from other incretin drugs, tirzepatide worked about as well as in the whole group.

    Peptide
    Tirzepatide
    Outcome
    Not applicableEfficacy in patients switching from incretin-based medications
    Study

    n = 828

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    This efficacy was consistent even in patients switching from incretin-based medications.
    2 context sentences
    Summary · context
    This multicenter retrospective observational study evaluated subjects with T2D who were treated with tirzepatide for ≥ 6 months across 10 medical centers in Hokkaido, Japan.
    Summary · context
    Of the 828 subjects analysed (mean age 55.6 ± 12.5 years; mean body mass index 30.6 ± 5.8), 81.3% were treated with incretin-based medications at baseline.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.